Vicore Pharma acquires shares in I-Tech

Vicore Pharma Holding AB (publ) (ticker: VICO) announces a share increase in I-Tech AB.

Vicore Pharma Holding AB has acquired shares in I-Tech AB from an existing shareholder with long ownership history in the company. Vicore Pharma Holding holds 26.5% of the shares in I-Tech which is an increase from previous 21% ownership after the acquisition. All issued shares were acquired by current shareholders in I-Tech in accordance with a pre-emption procedure.

"We have further increased our holding in I-Tech. We participated in a share issue in the end of 2017 and have in addition acquired shares in I-Tech from an existing shareholder. Although our main strategy and focus is drug development in the subsidiary Vicore Pharma, we identify a considerable financial value in investing further in I-Tech AB, which is developing very well at current, "says Per Jansson, CEO of Vicore Pharma Holding.

For further information, please contact
Per Jansson, CEO
M: +46 709 17 47 46 or e-mail: 
per.jansson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08.00 CET on February 8, 2018.

About Vicore Pharma Holding
Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. I-Tech AB has developed and commercialized a substance, Selektope® for use as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links